PURE Bioscience, Inc.

PURE Bioscience, Inc.

PURE
PURE Bioscience, Inc.US flagOther OTC
0.06
USD
-0.01
- -
6.71MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
0.14
0.08
0.02
0.02
0.02
0.03
0.03
0.03
0.08
0.05
0.02
0.02
0.02
0.02
Basic EPS, GAAP
-1.58
-0.71
-0.43
-0.19
-0.25
-0.1
-0.11
-0.09
- -
-0.03
-0.04
-0.04
-0.03
-0.03
Free Cash Flow per Basic Share
-1.04
-0.38
-0.25
-0.16
-0.09
-0.08
-0.06
-0.04
0.01
-0.02
-0.03
-0.03
-0.02
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-11.1
-6.46
-3.16
-2.22
-1.8
-1.71
-1.73
-1.68
-1.49
-1.43
-1.44
-1.19
-1.21
-1.23
Tangible Book Value per Share
-0.2
-0.22
-0.05
0.03
0.07
0.01
0.01
0.01
0.05
0.03
0.04
- -
-0.03
-0.04
Basic Weighted Avg Shares
6
11
26
40
57
63
67
73
82
87
89
111
112
112
Sales/Revenue/Turnover
1
1
1
1
1
2
2
2
7
4
2
2
2
2
Operating Margin (%)
-1,078.08
-827.8
-1,663.27
-1,048.01
-547.48
-328.13
-396.96
-292.77
0.06
-58.85
-181.87
-193.29
-159.5
-134.68
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-9
-8
-11
-8
-14
-6
-7
-7
- -
-2
-3
-4
-3
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,094.83
-935.49
-2,009.09
-1,046.23
-1,114.9
-342.05
-419.5
-343.32
0.06
-59.05
-188.4
-211.03
-170.66
-147.65
Working Capital
-1
-2
-1
1
4
- -
- -
- -
4
2
3
1
- -
- -
LT Debt
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
3
5
Total Equity
1
-1
- -
2
5
1
1
1
5
3
4
- -
-3
-5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
0.13
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-0.01
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Oct'25
Jan'25
Apr'25
ST Debt
- -
- -
- -
LT Borrowings
4
4
5
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
112
112
112
Market Capitalization
11
8
7

Working Capital

FRC

in mil. unless spec.
Oct'25
Jan'25
Apr'25
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,299.12%
-191.03%
-1,152.94%
Free Cash Flow
-50.91%
-87.93%
-23.56%
Net Income, GAAP
-5,811.86%
-11,625.3%
-15.43%
Sales/Revenue/Turnover
32.81%
34.44%
4.58%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
- -
- -
- -
2
2025
- -
- -
- -
1
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.01
-0.01
- -
-0.03
2025
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Robert F. Bartlett
Full Time Employees
11
Sector
Consumer Defensive
Industry
Household & Personal Products
Address
9669 Hermosa Avenue El Cajon CA United States of America 91730
IPO Date
Aug 8, 1996
Business
PURE Bioscience, Inc. (OTCQB: PURE) develops and commercializes proprietary antimicrobial products based on patented Silver Dihydrogen Citrate (SDC), a broad-spectrum, non-toxic agent stabilized with ionic silver, targeting pathogen and hygienic control challenges in health, environmental, and food safety applications; the company manufactures and distributes EPA-registered SDC-based disinfectants and sanitizers such as PURE Hard Surface, PURE Control produce wash, and membrane cleaning solutions for food-contact surfaces, equipment, and multi-surface use in food processing facilities; it also supplies SDC formulations as raw material ingredients to manufacturers of personal care products. Products feature low EPA toxicity ratings, no-rinse requirements, fast kill times against pathogens including Salmonella, Listeria, E. coli, and Norovirus, non-corrosive properties, minimal residue, and wastewater safety, with applications in dairy membrane treatment to reduce fouling, extend membrane life, and minimize downtime. Founded in 1992 and headquartered in El Cajon, California, the company primarily serves the food and beverage industry, including processors, restaurants, dairy plants, and produce operations, with geographic focus on the United States and regulatory registrations from the EPA, FDA, and Health Canada. In recent developments, PURE Bioscience expanded its distribution network through a multi-year agreement with Hydrite Chemical Company in January 2025 for food processing and dairy markets, following an eight-year relationship; it formed a strategic partnership with Bonsai in fiscal 2025 fourth quarter to enable direct-to-customer sales of SDC sanitizers and disinfectants via online platform; core business revenue grew 14% in the fiscal year ended July 31, 2025, amid development of membrane treatment technology for dairy and beverage sectors and ongoing R&D collaborations.

Company News

APIChat
  • Purecore Metals Announces Field Program Commencement at the Bankier Property

  • Purecore Engages HEG & Associates for its 2026 Exploration Program at the Bankier Property

  • Purecore Metals Inc. Announces Listing on the Canadian Securities Exchange Under the Symbol “PURE”

  • Caliber and PURE Pickleball & Padel Announce Building Permit Approval for World's Largest Indoor Pickleball and Padel Facility

  • PURE Bioscience Reports Fiscal Second Quarter 2026 Financial Results

  • Reviewing Green Thumb Industries (OTCMKTS:GTBIF) and PURE Bioscience (OTCMKTS:PURE)

  • Contrasting Agilent Technologies (NYSE:A) & PURE Bioscience (OTCMKTS:PURE)

  • PURE Property Management and HomeRiver Group Merge, Secure $80 Million in Growth Capital

  • PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results

  • PURE Bioscience, Inc. Announces Leadership Promotions

  • CORVEX TO GO PUBLIC IN ALL-STOCK MERGER WITH MOVANO, CREATING A PURE-PLAY PLATFORM FOR SECURE AI INFRASTRUCTURE AND HIGH-PERFORMANCE INFERENCE

  • PURE Bioscience (OTCMKTS:PURE) Sees Significant Drop in Short Interest

  • PURE Bioscience Reports Fiscal 2025 Financial Results

  • PURE Insurance Enhances Member Billing Experience with Upgrade to Duck Creek Billing

  • PURE Bioscience Partners with Bonsai for Direct-to-Customer Sales

  • PURE STORAGE UNVEILS NEXT-GENERATION STORAGE PRODUCTS TO DELIVER PERFORMANCE AT ANY SCALE

  • PURE STORAGE INTRODUCES THE ENTERPRISE DATA CLOUD SO CUSTOMERS CAN MANAGE THEIR DATA, NOT THEIR STORAGE

  • PURE Bioscience Reports Fiscal Third Quarter 2025 Financial Results

  • PURE Bioscience Unveils Revolutionary Membrane Treatment Solution for the Dairy and Beverage Industry

  • PURE STORAGE AND SK HYNIX COLLABORATE TO DELIVER PERFORMANCE AND ENERGY EFFICIENCY IN HYPERSCALE DATA CENTERS